Number of pages: 100 | Report Format: PDF | Published date: September 08, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market size value in 2021 |
USD 2.3 Billion |
Revenue forecast in 2030 |
USD 8.28 Billion |
Growth Rate |
CAGR of 15.3% from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast period |
2022-2030 |
Segments covered |
Treatment Type, End User, and Region |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global sickle cell disease treatment market was pegged at US$ 2.3 billion in 2021 and is expected to register a revenue CAGR of 15.3% during the forecast period.
Market Fundamentals
Red blood cells (RBCs) with aberrant, rigid sickle shapes are the hallmark of sickle cell disease (SCD), a genetic blood illness brought on by mutations in the beta-globin gene. From person to person, the disease's severity varies greatly. This illness is characterized by a low level of red blood cells (anemia), recurrent infections, and cyclical pain episodes. The rising prevalence of sickle cell illness is the major factor fueling the revenue growth of the sickle cell treatment market.
[3434334]
Market Dynamic
The rising prevalence of sickle cell illness is the main factor fueling the revenue growth of the sickle cell treatment market. Additionally, rising R&D activities, a strong pipeline, and a growing patient base are all expected to have a positive impact on the market revenue growth. The global sickle cell disease treatment market revenue growth is expected to be driven by several factors, including an increase in immigration, better healthcare services, and a large population of people of African heritage. To some extent, the market's revenue expansion is also influenced by the approval of new products.
The revenue growth of the market is constrained by the high cost of the treatment. Patients stop taking their medication in the middle of dosage because of the expensive lifelong treatment and a lack of reimbursement.
Market Ecosystem
The global sickle cell disease treatment market is analyzed from three perspectives: treatment type, end-user, and region.
Sickle Cell Disease Treatment Market by Treatment Type
[52342343]
Based on treatment type, the global sickle cell disease treatment market is segmented into, pharmacotherapy, bone marrow transplant, and blood transfusion.
The blood transfusion segment is expected to register stable revenue growth during the forecast period. The increased demand for blood transfusions in sickle cell therapy and the rise in SCD prevalence are expected to drive the revenue growth of the segment. The ability to get normal red blood cells through blood transfusions increases hemoglobin levels to improve oxygen delivery in the body, lowering sickle cell anemia and the drive to produce more sickle cells.
The bone marrow transplant (BMT) segment is expected to register significant revenue growth because it is the only treatment for sickle cell disease, hence the preference for this therapy option is increasing to some extent, lately.
Sickle Cell Disease Treatment Market by End User
Based on the end user, the global sickle cell disease treatment market is segmented into hospitals and specialty clinics.
Vaso occlusive crisis is the primary factor driving sickle cell disease patients to hospitals, hence the hospital segment dominates the sickle cell disease treatment market in terms of revenue share.
Sickle Cell Disease Treatment Market by Region
Based on region, the global sickle cell disease treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominates the overall sickle cell disease treatment market, with the United States being the major contributor to the market revenue. The revenue growth in the region is attributed to improving access to sickle cell disease treatment and potential pipeline candidates. Additionally, increasing births with sickle cell disease in the US is also increasing the demand for sickle cell treatment in this region.
Competitive Landscape
The prominent players operating in the global sickle cell disease treatment market are:
Strategic Developments
The global sickle cell disease treatment market is expected to register at a revenue CAGR of 15.3% during the forecast period.
Increased research in the field of rare diseases is one of the key factors governing the revenue growth of the global sickle cell disease treatment market.
Eli Lilly, AstraZeneca, and Pfizer are among the key players operating in the global sickle cell disease treatment market.
The blood transfusion segment dominates the global sickle cell disease treatment in terms of market revenue.
Asia Pacific region is expected to register the highest revenue CAGR during the forecast period.
*Insights on financial permanence is subject to availability of information in public domain